Sentence: A Phase II trial reported a median OS duration of 8.6 months for patients receiving cetuximab plus irinotecan , plus a median time to progression of 4.1 months , a tumour response rate of 22.9 % and suggested that treatment with cetuximab in combination with irinotecan is associated with significantly more adverse events ( any grade 3 or grade 4 adverse event ) than cetuximab monotherapy .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['cetuximab', 'irinotecan'], 'is_context_needed': True}]